文献速递淋巴瘤

弥漫大细胞淋巴瘤中期FDG-PET的预后价值:CALGB 50303临床试验结果

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial.
PubMed 文献 · Blood · 2020-01-01

在大细胞淋巴瘤随机前瞻性临床试验中,于基线、2周期化疗后(中期PET)和治疗结束时行FDG-PET,核心实验室用Deauville 5分量表(5-PS)和FDG摄取变化百分比(ΔSUV)判读。158例可分析患者中,中期PET的ΔSUV≥66%可预测总生存(HR 0.31),但视觉5-PS未预测结局。

要点

  • 中期PET的ΔSUV≥66%可预测总生存(HR 0.31;95%CI 0.11-0.85;P=.02)。
  • 中期PET视觉5-PS未预测结局。
  • 事件数少限制了统计分析。

核心结论

  • 在弥漫大B细胞淋巴瘤(DLBCL)中,中期PET的ΔSUV可预测总生存,而视觉分析未预测结局,但事件数少限制了统计分析。
  • 这些数据可能有助于指导未来使用PET反应适应治疗的临床试验。

研究设计与样本

  • 作为大细胞淋巴瘤随机前瞻性临床试验的一部分,在基线、2周期化疗后(中期PET)和治疗结束时行系列FDG-PET。
  • 扫描由核心实验室2名影像学专家判读,使用视觉Deauville 5分量表(5-PS)并计算FDG摄取变化百分比(ΔSUV)。
  • 母试验入组524例患者,其中169例同意加入PET亚研究,158例符合最终分析条件。
  • 视觉评分1至3分和ΔSUV≥66%被前瞻性定义为阴性。
  • 该试验在www.clinicaltrials.gov注册为#NCT00118209。

主要发现

  • 在该选定人群中,所有患者基线均为FDG高摄取疾病;按5-PS,中期PET时55例(35%)仍为阳性,治疗结束时PET时28例(18%)为阳性。
  • 中期PET的中位ΔSUV为86.2%。
  • 中位随访5年,ΔSUV作为连续变量与无进展生存(PFS)相关(风险比[HR]=0.99;95%置信区间[CI] 0.97-1.00;P=.02),与总生存(OS)相关(HR 0.98;95%CI 0.97-0.99;P=.03)。
  • ΔSUV≥66%可预测OS(HR 0.31;95%CI 0.11-0.85;P=.02),但未预测PFS(HR 0.47;95%CI 0.19-1.13;P=.09)。
  • 中期PET的视觉5-PS未预测结局。

关键数值与推荐

  • 视觉Deauville 5分量表(5-PS)评分1至3分定义为阴性。
  • ΔSUV≥66%定义为阴性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 事件数少限制了统计分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As part of a randomized, prospective clinical trial in large cell lymphoma, we conducted serial fluorodeoxyglucose positron emission tomography (FDG-PET) at baseline, after 2 cycles of chemotherapy (interim PET [i-PET]), and at end of treatment (EoT) to identify biomarkers of response that are predictive of remission and survival. Scans were interpreted in a core laboratory by 2 imaging experts, using the visual Deauville 5-point scale (5-PS), and by calculating percent change in FDG uptake (change in standardized uptake value [ΔSUV]). Visual scores of 1 through 3 and ΔSUV ≥66% were prospectively defined as negative. Of 524 patients enrolled in the parent trial, 169 agreed to enroll in the PET substudy and 158 were eligible for final analysis. In this selected population, all had FDG-avid disease at baseline; by 5-PS, 55 (35%) remained positive on i-PET and 28 (18%) on EoT PET. Median ΔSUV on i-PET was 86.2%. With a median follow-up of 5 years, ΔSUV, as continuous variable, was associated with progression-free survival (PFS) (hazard ratio [HR] = 0.99; 95% confidence interval [CI], 0.97-1.00; P = .02) and overall survival (OS) (HR, 0.98; 95% CI, 0.97-0.99; P = .03). ΔSUV ≥66% was predictive of OS (HR, 0.31; 95% CI, 0.11-0.85; P = .02) but not PFS (HR, 0.47; 95% CI, 0.19-1.13; P = .09). Visual 5-PS on i-PET did not predict outcome. ΔSUV, but not visual analysis, on i-PET predicted OS in DLBCL, although the low number of events limited the statistical analysis. These data may help guide future clinical trials using PET response-adapted therapy. This trial was registered at www.clinicaltrials.gov as #NCT00118209.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Schöder H, Polley MC, Knopp MV, et al. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood. 2020. PMID: 32232481. doi:10.1182/blood.2019003277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。